Denali Therapeutics Inc represents a strong commitment to scientific innovation and the development of transformative therapies for neurodegenerative diseases. With a focus on precision medicine and antibody-based therapies, Denali aims to improve the lives of patients by targeting the underlying causes of these devastating conditions. The company's corporate philosophy revolves around collaboration, integrity, and a patient-centric approach. Denali Therapeutics Inc is dedicated to advancing research, leveraging cutting-edge technologies, and forging strategic partnerships to bring about meaningful advancements in the treatment of neurodegenerative disorders.

Denali Therapeutics Inc is primarily present in the United States. With headquarters in South San Francisco, California, the company operates mainly in its home country. As a biotechnology company focused on neurodegenerative diseases, Denali Therapeutics Inc conducts research and development activities within the United States, collaborating with various academic institutions, healthcare professionals, and industry partners nationwide. The company's commitment to advancing therapies for conditions like Alzheimer's and Parkinson's disease is largely focused on the American market, with potential expansion opportunities in the future.

Denali Therapeutics Inc has achieved several significant milestones. The company successfully completed its initial public offering (IPO) in December 2017, raising approximately $250 million in proceeds. Additionally, Denali has formed several strategic collaborations with prominent pharmaceutical companies, including Sanofi and Takeda, to accelerate the development of innovative therapies for neurodegenerative diseases. Denali's productive research and drug discovery efforts led to the advancement of several promising drug candidates into clinical trials. The company also received Fast Track designation from the U.S. FDA for its investigational therapy targeting a genetic form of ALS. Denali Therapeutics continues to make impressive progress in its mission to discover and develop effective treatments for neurodegenerative diseases.

Denali Therapeutics Inc is a biotechnology company focused on developing therapies for neurodegenerative diseases. Founded in 2015, the company is headquartered in South San Francisco, California. Denali's approach combines proprietary drug delivery technologies with their deep understanding of neurodegenerative diseases. With a mission to defeat neurodegeneration, Denali Therapeutics undertakes rigorous research and development to address diseases like Alzheimer's, Parkinson's, and ALS. By leveraging their innovative portfolio and strategic partnerships, Denali Therapeutics aims to bring effective treatments to patients in need, ultimately improving the quality of life for individuals affected by neurodegenerative disorders.

The main competitors of Denali Therapeutics Inc in the market include Biogen Inc., Ionis Pharmaceuticals Inc., and Voyager Therapeutics Inc. These companies are actively engaged in the development and commercialization of innovative therapies in the field of neurodegenerative diseases, emphasizing the treatment of conditions such as Parkinson's disease and Alzheimer's disease. Through their robust research and development efforts, these competitors pose a significant challenge to Denali Therapeutics Inc's goal of providing effective and groundbreaking solutions for patients suffering from neurodegenerative disorders.

Denali Therapeutics Inc is primarily active in the biotechnology and pharmaceutical industries.

Denali Therapeutics Inc is a biotechnology company that focuses on the development and commercialization of therapeutics for neurodegenerative diseases. They employ a unique business model that combines rigorous scientific research with strategic partnerships and collaborations. By leveraging their expertise in the field of neuroscience, Denali Therapeutics aims to identify and target key pathways involved in neurodegenerative diseases, such as Alzheimer's and Parkinson's. Their goal is to develop innovative therapies that can potentially slow down or even halt disease progression, ultimately improving patients' lives. With a strong emphasis on research and development, Denali Therapeutics strives to bring novel treatment options to patients in need.

Denali Therapeutics hissesinin F/K oranı -7,45.

Denali Therapeutics KUV 59,34 dir.

Denali Therapeutics için AlleAktien Kalite Skoru 1/10'dur.

beklenen Denali Therapeutics cirosu 48,94 Milyon. USD dir.

beklenen Denali Therapeutics karı -389,79 Milyon. USD olarak gerçekleşmiştir.

Denali Therapeutics Inc. is a biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of neurodegenerative diseases. The company is based in South San Francisco, California and was founded in 2015. Denali Therapeutics' business model is based on the exploration of novel drugs targeting a variety of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis (ALS), and frontotemporal dementia. The company works closely with clinicians, pharmacy manufacturers, and scientists to develop more innovative and effective therapeutic approaches for these severe conditions. Denali Therapeutics has directed its development platform towards various main areas, including the discovery and development of novel treatment approaches such as antibodies and specific drugs targeting abnormal proteins such as tau, alpha-synuclein, and huntingtin. The company also focuses on gene therapies to combat genetic defects leading to neurodegenerative diseases. Additionally, the company has developed small molecules that prevent protein aggregation in cells. Currently, Denali Therapeutics has three main products in its pipeline. One of them is DNL747, which activates a key receptor in the brain that can help reduce inflammatory reactions associated with a variety of neurodegenerative and autoimmune diseases. DNL758 is a clinically tested selective inhibitor of receptor-interacting protein kinases (RIPK) developed for the treatment of Alzheimer's disease. Finally, DNL310 is specifically designed to protect the brains of patients with Gaucher's disease or Parkinson's disease. The company is likely to generate solid revenues in the near future. In April 2021, Denali Therapeutics reported positive safety data and signaling measurements from Phase 1B/2A studies of their main product, an LRRK2 inhibitor, in Parkinson's disease patients, which could potentially indicate clinical efficacy. Denali Therapeutics also leverages potential partnerships that can cover the entire value chain from research and development to commercialization. In 2018, Denali Therapeutics entered a partnership with Takeda Pharmaceutical, a Japanese pharmaceutical company, to further explore and develop therapeutics for neurodegeneration. Another significant strategic partner of Denali Therapeutics is Sanofi, a global biopharmaceutical company that contracted the company in October 2020 to develop their customized antibodies against neurodegeneration. Overall, Denali Therapeutics is focused on developing and distributing groundbreaking therapies for severe neurodegenerative diseases. In the future, Denali Therapeutics remains a promising player in the field of neurodegeneration with real market prospects.

Denali Therapeutics, yılda kez dağıtılmak üzere 0 USD tutarında temettü ödemektedir.

Denali Therapeutics için şu an için temettü hesaplanamıyor veya şirket temettü dağıtmıyor.

Denali Therapeutics şirketinin ISIN kodu US24823R1059’dir.

Denali Therapeutics 'nin WKN'si A2H9G8 'dir.

Denali Therapeutics için Ticker DNLI’dir.

Son 12 ay içerisinde Denali Therapeutics, tutarında bir temettü ödedi. Bu, yaklaşık olarak oranında bir temettü verimine denk gelmektedir. Gelecek 12 ay için Denali Therapeutics, tahmini olarak 0 USD tutarında bir temettü ödemesi yapacak.

Denali Therapeutics şirketinin mevcut temettü verimi .

Denali Therapeutics dönemsel olarak temettü ödemesi yapar. Bu ödemeler aylarında gerçekleştirilir.

Denali Therapeutics, son 0 yıl içerisinde her yıl temettü ödedi.

Önümüzdeki 12 ay için 0 USD tutarında temettü ödenmesi beklenmektedir. Bu, 0 % oranında bir temettü verimidir.

Denali Therapeutics, 'Sağlık' sektörüne atanmıştır.

Son Denali Therapeutics tarihinde 0 USD tutarındaki en son temettüyü alabilmek için, hisseyi 08.07.2024 tarihindeki Ex-Tag'den önce portföyünde bulundurman gerekiyordu.

Son ödeme tarihi 08.07.2024 olarak gerçekleşti.

2023 yılında Denali Therapeutics tarafından 0 USD olarak temettüler dağıtıldı.

Denali Therapeutics hisselerinin temettüleri USD olarak dağıtılır.